Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.
about
MicroRNAs and Potential Targets in Osteosarcoma: ReviewCalcium-Sensing Receptor in Breast Physiology and CancerG9A performs important roles in the progression of breast cancer through upregulating its targets.Optimization and In Vivo Profiling of a Refined Rat Model of Walker 256 Breast Cancer Cell-Induced Bone Pain Using Behavioral, Radiological, Histological, Immunohistochemical and Pharmacological MethodsmiR-203 Acts as a Tumor Suppressor Gene in Osteosarcoma by Regulating RAB22AmiR-135a Inhibits the Invasion of Cancer Cells via Suppression of ERRα.Aryl hydrocarbon receptor-microRNA-212/132 axis in human breast cancer suppresses metastasis by targeting SOX4miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1.MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosismiR-203 facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancerTCF-1 participates in the occurrence of dedifferentiated chondrosarcomamiR-203 inhibits the traumatic heterotopic ossification by targeting Runx2.EGR1 mediates miR-203a suppress the hepatocellular carcinoma cells progression by targeting HOXD3 through EGFR signaling pathway.MiR-451 Promotes Cell Proliferation and Metastasis in Pancreatic Cancer through Targeting CAB39.A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice.Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells.Systemic RALA/iNOS Nanoparticles: A Potent Gene Therapy for Metastatic Breast Cancer Coupled as a Biomarker of Treatment.MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.Non-coding RNAs: Epigenetic regulators of bone development and homeostasis.Mechanisms of osteolytic and osteoblastic skeletal lesions.Direct interaction between miR-203 and ZEB2 suppresses epithelial-mesenchymal transition signaling and reduces lung adenocarcinoma chemoresistance.Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid CancerThe role of microRNAs in bone metastasis.Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development.Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.Runx2 and microRNA regulation in bone and cartilage diseases.Runx Genes in Breast Cancer and the Mammary Lineage.Serum miRNA Signatures Are Indicative of Skeletal Fractures in Postmenopausal Women With and Without Type 2 Diabetes and Influence Osteogenic and Adipogenic Differentiation of Adipose Tissue-Derived Mesenchymal Stem Cells In Vitro.Downregulation of Potential Tumor Suppressor miR-203a by Promoter Methylation Contributes to the Invasiveness of Gastric Cardia Adenocarcinoma.miR-203 and miR-320 Regulate Bone Morphogenetic Protein-2-Induced Osteoblast Differentiation by Targeting Distal-Less Homeobox 5 (Dlx5)miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis.Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension.Cadherin 6 is activated by Epstein-Barr virus LMP1 to mediate EMT and metastasis as an interplay node of multiple pathways in nasopharyngeal carcinoma.miR‑203‑3p participates in the suppression of diabetes‑associated osteogenesis in the jaw bone through targeting Smad1.Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention.MicroRNA-590-5p Stabilizes Runx2 by Targeting Smad7 During Osteoblast Differentiation.Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.
P2860
Q26784033-F147E0E1-524E-4A5E-AC69-9A99CBEAC3F3Q28071486-DB4ADBE8-0510-4450-A39C-2DE02D9F81FFQ33751161-F83AB6C1-6DF1-4072-A432-41A3CF617859Q33875227-26288A36-7BAB-48AB-967E-E0E46A6DCC1DQ35780039-2FF654B9-7E93-4A89-9A39-50B0CDBAD766Q36030509-FBAAB84D-65DF-485F-B261-6268E55C4806Q36069377-F01D946C-204E-4C89-BFF7-1E5B09EAF4D9Q36548645-7496D33F-269D-4D3B-9E10-9805CA52BAC8Q37080584-41F746FB-2566-44B7-BAF3-2A30FDB680A6Q37190115-B30C96BF-AB05-49C0-A491-0FC6961DD1D4Q37344496-2BBD4D1E-1361-4959-A7A1-E79090E9419DQ37396044-E1707FE3-ECB8-4207-BC00-3BDBDC4CFA3DQ37465938-D5D7EDDD-9065-425E-9462-612A79344C5FQ37564406-B23A6E65-2097-419C-8EF7-88DC1AC2889CQ37620221-4BCE75F0-74FB-4DC0-80B3-67FE384DA8CBQ37688549-29CF5688-EF78-4DDB-B224-8539C5473889Q37694746-CB51894A-8C91-411D-9293-1700843F95CEQ37718207-6BABC6E7-D301-4A72-B651-69B6B433E7FAQ37744995-691805DE-A776-4E9C-AE96-83B7AFFB56C8Q38514715-FF6ECBC7-F874-4639-B043-980E31C87F86Q38625793-938B8B0C-3170-46AE-84C0-50E82A2C45B0Q38735878-A340A129-9121-4DA1-9C4E-11564284B57DQ38766996-8F80D978-4199-4B1F-87F1-BC74AB83A668Q38808905-73D6655A-AB69-407E-89AE-3330E2384CE6Q38818836-61A5C0B6-EA45-49F1-B316-A950811C5D63Q38835737-00BD0FA4-B92D-426D-BF47-6A1BBAEEEDCEQ38928077-098EC20D-061D-4BAE-B8F4-C1960BD0A8E2Q39181420-AAC258A0-6B1C-4070-B8E0-4F0874EF7E1BQ39654135-DF6A2BEB-1973-4032-B984-D3EB387B05E9Q40507688-F8CACB4C-2127-4513-B640-E670FFBF2F13Q41819664-8CA51402-BD35-43B0-96A7-2F771FEDF86CQ41975973-940EC843-B9B7-4002-AC27-212774B9DB69Q44871921-4A91C141-FA65-4AE9-8613-4BC61B3CCA7BQ46277870-C558AA36-1DDB-4036-A57D-87AC5A2B7C3EQ47248660-189E5B4E-3B5C-45B3-8DBF-495BAA379A2EQ50068015-6A1AEC08-D039-4A86-BE68-4755F18CA576Q52646480-100DE436-9D16-403B-9E78-4A32E336B4D5Q52718880-4D2E58B7-6DE8-4D3B-83B8-DF4F00BF5013Q52978300-3F74623F-785A-4D72-A332-096DE42D156DQ53197894-A287ED23-36AC-45B0-9CCF-EC0E1C0B0D2B
P2860
Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Targeting of Runx2 by miR-135 ...... r and Metastatic Bone Disease.
@ast
Targeting of Runx2 by miR-135 ...... r and Metastatic Bone Disease.
@en
type
label
Targeting of Runx2 by miR-135 ...... r and Metastatic Bone Disease.
@ast
Targeting of Runx2 by miR-135 ...... r and Metastatic Bone Disease.
@en
prefLabel
Targeting of Runx2 by miR-135 ...... r and Metastatic Bone Disease.
@ast
Targeting of Runx2 by miR-135 ...... r and Metastatic Bone Disease.
@en
P2093
P2860
P1433
P1476
Targeting of Runx2 by miR-135 ...... r and Metastatic Bone Disease.
@en
P2093
Andre J van Wijnen
Eric Hesse
Gary S Stein
Gillian Browne
Hanna Taipaleenmäki
Jacqueline Akech
Jane B Lian
Janet L Stein
Jozef Zustin
P2860
P304
P356
10.1158/0008-5472.CAN-14-1026
P407
P577
2015-01-29T00:00:00Z